临床试验中终点成熟时间的实时监测与预测
该文提出一种基于模拟的框架,整合中心启动时间、受试者入组时间和事件时间,以实时预测终点成熟时间(TTEM)。采用非齐次泊松过程与Weibull、分段指数及模型平均等事件时间模型,在模拟和14项肿瘤试验的31个研究-终点组合中验证,预测精度较常用商业软件最高提升54%。
要点
- TTEM定义为达到或观察到特定数量或百分比终点所需的时间。
- 该框架整合中心启动、受试者入组和事件时间,实现实时预测。
- 在真实肿瘤试验中,预测精度较常用方法最高提升54%。
核心结论
- 所提出的基于模拟的框架在模拟和真实数据中均能显著提高TTEM预测精度,较常用方法最高提升54%。
研究设计与样本
- 研究提出一种基于模拟的框架,结合中心启动时间、受试者入组时间和事件时间预测TTEM;采用非齐次泊松过程(二次时变率函数)建模中心启动与入组,并整合Weibull、分段指数和模型平均等事件时间模型。
- 通过广泛模拟评估预测性能,并将方法应用于14项随机选取的肿瘤学2期和3期研究(涵盖实体瘤和血液肿瘤),共31个研究-终点组合。
- 将所提方法的预测性能与常用商业软件East(Cytel,Cambridge,MA,USA)进行比较。
主要发现
- 在模拟和真实数据中,所提方法较常用方法可显著提高预测精度,最高提升54%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In clinical trials, almost all key milestone dates can be defined in terms of time to endpoint maturation (TTEM). The real time monitoring and accurate prediction of TTEM have a significant impact on clinical trial planning and execution and can bring significant value to clinical trial practitioners. TTEM is defined as the time to achieve or observe a certain number or percentage of some endpoint of interest. It is a combination of time to site initiation, time to subject enrollment after site initiation and time to event of interest after subject enrollment. To better predict TTEM during the trial, the future site initiation and subject enrollment have to be taken into account while predicting the number of events. In this article, we propose a novel simulation-based framework combining time to site initiation, time to subject enrollment and time to event in order to predict TTEM. A nonhomogeneous Poisson process with a quadratic time-varying rate function is used to model site initiation and subject enrollment and more advanced time to event models had been explored and integrated on top of them, such as Weibull, piecewise exponential, and model averaging which is equivalent to a Bayesian model selection strategy. To evaluate the predictive performance of the proposed methodology, we conducted extensive simulations and applied the methodology to 14 randomly selected real oncology phase 2 and phase 3 studies in both solid tumor and hematology with a total 31 study-endpoint combinations. The predictive performance of the proposed methodology was then compared with popular and commonly available commercial software, for example, East (Cytel, Cambridge, MA, USA). From both simulation and real data, the proposed methodology can significantly improve the prediction accuracy by up to 54% compared to the commonly available method.
引用
- Wang L, Liu Y, Chen X, et al. Real time monitoring and prediction of time to endpoint maturation in clinical trials. Stat Med. 2022. PMID: 35587584. doi:10.1002/sim.9436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。